“The Company was not subject to any material legal proceedings during the six months ended June 30, 2026 and 2025 and, to the best of its knowledge, no material legal proceedings are currently pending or threatened.”10-Q · Jul 30, 2026 ↗
Disc Medicine, Inc.
IRON
Market read
Disc Medicine, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- R&D personnel-related costs increased $7.1M, including a $2.8M rise in stock-based compensation tied to equity awards.
- SG&A personnel-related costs increased $8.7M contributing to an $11.4M total increase; includes $2.8M stock-based comp and $1.6M restructuring.
Invalidation: The isolated read changes if IRON's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- R&D personnel-related costs increased $7.1M, including a $2.8M rise in stock-based compensation tied to equity awards.
- SG&A personnel-related costs increased $8.7M contributing to an $11.4M total increase; includes $2.8M stock-based comp and $1.6M restructuring.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Product pipeline and R&D has repeated favorable evidence across 5 filings.
No qualifying adverse evidence was identified; that is not proof there is no downside.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 10, 2026
74.20What management says matters
Persistent and emerging business drivers
“The increase of $18.8 million was primarily due to an increase of $13.1 million in personnel-related costs related to higher research and development headcount, including an increase of $6.0 million in stock-based 22 compensation driven by awards granted unde…”10-Q · Jul 30, 2026 ↗
“Other income (expense), net consists primarily of interest income from our cash, cash equivalents and marketable securities, partially offset by interest expense associated with our term loan.”10-Q · Jul 30, 2026 ↗
“The increase of $14.5 million was primarily due to an increase of $12.6 million in personnel-related costs due to increased selling, general and administrative headcount, including an increase of $5.1 million in stock-based compensation driven by awards grant…”10-Q · Jul 30, 2026 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for IRON. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for IRON. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind IRON
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
HTGCHercules Capital, Inc.partnerNov 6, 2025 ▾
“We may also pursue additional cash resources through public or private equity offerings, collaborations or additional draws under the Hercules Loan Agreement.”
HTGCHercules Capital, Inc.lenderMay 5, 2026 ▾
“Interest Expense Interest expense primarily consists of amortization of debt issuance costs and discount and interest expense under the Hercules Loan Agreement.”
ABBVAbbVie Inc.partnerNov 6, 2025 ▾
“We are party to license agreements with Roche, AbbVie and Mabwell and we may from time to time in the future be party to other license and collaboration agreements with third parties to advance our research or allow commercialization of current or future prod…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IRON is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for IRON; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.